Arcus Biosciences(US:RCUS)2026-02-25 21:11Financial Performance - Total revenues for 2025 decreased to $247 million, a 4% decline from $258 million in 2024, primarily due to lower revenue from collaborations with Taiho and Gilead [398]. - The net loss for 2025 was $353 million, a 25% increase compared to a net loss of $283 million in 2024 [397]. - Non-operating income decreased to $33 million in 2025, a 31% decline from $48 million in 2024, primarily due to lower interest income [408]. - Cash used in operating activities was $482 million in 2025, significantly higher than $170 million in 2024, largely due to increased R&D expenditures [420]. - Total operating expenses for 2025 were $633 million, an 8% increase from $588 million in 2024 [397]. Research and Development - The median progression-free survival (mPFS) for the pooled analysis of the HIF-2α inhibitor casdatifan was 12.2 months, with a 15.2 months median follow-up [373]. - The confirmed overall response rate for casdatifan plus cabozantinib in metastatic cancer patients was 46% [373]. - The company plans to decrease R&D expenses in the near term as it winds down studies for domvanalimab, while increasing investment in casdatifan and inflammation programs [391]. - The Phase 3 STAR-221 study was discontinued due to futility, as the domvanalimab-based combination did not improve overall survival compared to nivolumab plus chemotherapy [380]. - The company completed enrollment of the PRISM-1 trial within 12 months of initiation, evaluating quemliclustat in pancreatic cancer [380]. - The company expects to incur substantial expenditures for the development and potential commercialization of investigational products and ongoing R&D programs [384]. Cash and Financing - As of December 31, 2025, the company had $1.0 billion in cash, cash equivalents, and marketable securities, expected to fund operations until at least the second half of 2028 [385]. - In 2025, the company raised approximately $438 million through two underwritten offerings of common stock [417]. - The company has outstanding long-term debt with a carrying value of $99 million as of December 31, 2025, compared to $48 million in 2024 [445]. - Cash provided by financing activities for 2023 includes net proceeds of $25 million from common stock issuance and $8 million from equity award plans [427]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $1.0 billion, up from $992 million in 2024 [444]. Collaboration and Revenue Recognition - The company received $37 million in collaboration payments in 2025, a significant decrease from $232 million in 2024 [420]. - The company recognized a cumulative catch-up to revenue of $143 million due to a contract modification related to the Gilead collaboration [436]. - At December 31, 2025, the company had $37 million in deferred revenue related to R&D programs that are satisfied over time [439]. - A hypothetical 5% increase in the total estimated effort required to satisfy performance obligations could increase related revenue recognized by $28 million [440]. - The company is contractually obligated to make significant payments upon achieving various development, regulatory, and commercial milestones [429]. Market Risks - The company is exposed to market risks from changes in interest rates and foreign currency exchange rates [443]. - A hypothetical 100 basis point increase in interest rates would not materially affect the fair market value of cash, cash equivalents, and marketable securities [444]. - A hypothetical 20% adverse movement in foreign currency exchange rates would not result in a material impact on the company's financial position or income [446]. Shareholder Information - Gilead holds approximately 25.1% of the company's outstanding common stock as of December 31, 2025 [379].